Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncternal Therapeutics : , Celularity Collaborating on Targeted Placental-Derived Cellular Therapies

09/20/2021 | 10:32am EST


ę MT Newswires 2021
All news about ONCTERNAL THERAPEUTICS, INC.
12/01Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5..
AQ
11/15ONCTERNAL THERAPEUTICS : ONCT-216 - Ravin 2021 CTOS Oral Presentation Slides
PU
11/15Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT..
AQ
11/15Oncternal Therapeutics, Inc. Presents Updated Interim Phase 1/2 Clinical Trial Data for..
CI
11/09Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Confer..
GL
11/04ONCTERNAL THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/04ONCTERNAL THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
11/04Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/04Corporate Presentation, November 2021
PU
11/04Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
AQ
More news
Analyst Recommendations on ONCTERNAL THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 5,02 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 142 M 142 M -
Capi. / Sales 2021 28,3x
Capi. / Sales 2022 43,4x
Nbr of Employees 13
Free-Float 88,2%
Chart ONCTERNAL THERAPEUTICS, INC.
Duration : Period :
Oncternal Therapeutics, Inc. Technical Analysis Chart | ONCT | US68236P1075 | MarketScreener
Technical analysis trends ONCTERNAL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,87 $
Average target price 15,50 $
Spread / Average Target 440%
Managers and Directors
James B. Breitmeyer President, Chief Executive Officer & Director
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer
David F. Hale Chairman
Rajesh Krishnan Chief Technology Officer
Gunnar F. Kaufmann Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCTERNAL THERAPEUTICS, INC.-41.43%142
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745